XPAR
VETO
Market cap996mUSD
Oct 07, Last price
76.50EUR
1D
0.66%
1Q
7.29%
Jan 2017
68.02%
IPO
232.61%
Name
Vétoquinol
Chart & performance
P/E
15.52
P/S
1.69
EPS
4.93
Div yield, %
1.16%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
4.22%
Revenues
526m
-2.50%
Net income
57m
-2.36%
CFO
72m
-16.02%
Dividend
Jun 03, 20260.93 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vetoquinol S.A. is a pharmaceutical company dedicated to animal health, responsible for researching, formulating, and distributing veterinary medicines and other health-related products throughout Europe, the Americas, and the Asia Pacific. The firm offers a comprehensive range of solutions for various therapeutic areas, including pain and mobility management, inflammatory conditions, dermatology, hygiene, parasite control, udder health, infectious diseases, reproductive care, behavioral issues, internal medicine, and cardiovascular-renal disorders. These products are developed for a diverse clientele of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside domestic dogs. Founded in 1933, Vetoquinol S.A. maintains its headquarters in Lure, France, and operates as a subsidiary of Soparfin SCA.
Related entities
Parent
SOPARFIN
Subsidiaries
VETOQUINOL INTERNATIONAL
Key people
Alain Masson
Deputy Chief Executive Officer, Pharmacist Manager, Quality Director · since 2008
Regis Vimal Vimal du Monteil
Member of the Executive Committee, Group Director - Finance and Legal Affairs · since 2010
Hans Hollegien
Member of the Executive Committee, Group Director - Marketing and Communication
Isabelle Proust-Cabrera
Member of the Executive Committee, Group Director - Human Resources
Alain Chaptal
Member of the Executive Committee, Group Director - Manufacturing and Quality Operations
Dominique Derveaux
Member of the Executive Committee, Group Director - Europe
Thomas Robitaille
Member of the Executive Committee, Group Director - Americas
Dan Tasli
Member of the Executive Committee, Group Director - Commercial Division, Asia and Distributors Worldwide
Marie-Josephe Baud
Director · since 2013
Matthieu Frechin
Chief Executive Officer, Member of the Executive Committee, Director · since 2010
Francois Frechin
Director · since 1975
Martine Frechin
Director · since 2004
Etienne Frechin
Chairman of the Board · since 2010
Philippe Arnold
Independent Director · since 2007
Louis Champel
Independent Director · since 2009
Headquarters & legal address
Village
MAGNY-VERNOIS 70200
FR
MAGNY-VERNOIS 70200
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||